INDEMNIFICATION AGREEMENTIndemnification Agreement • June 5th, 2020 • Akouos, Inc. • Pharmaceutical preparations • Delaware
This Indemnification Agreement (“Agreement”) is made as of [ ], 20[ ] by and between Akouos, Inc., a Delaware corporation (the “Company”), and [ ] (“Indemnitee”) [[Solely with respect to officers and directors that execute this form of indemnification agreement on or prior to the Company’s initial public offering:] and shall be effective as of the effectiveness of a Registration Statement on Form S-1 relating to the initial registration under the Securities Act of 1933, as amended, of shares of the Company’s common stock].
Akouos, Inc. STOCK OPTION AGREEMENTStock Option Agreement • June 5th, 2020 • Akouos, Inc. • Pharmaceutical preparations
This option satisfies in full all commitments that the Company has to the Participant with respect to the issuance of stock, stock options or other equity securities.
Akouos, Inc. RESTRICTED STOCK UNIT AGREEMENTRestricted Stock Unit Agreement • June 5th, 2020 • Akouos, Inc. • Pharmaceutical preparations • Delaware
This grant of RSUs satisfies in full all commitments that the Company has to the Participant with respect to the issuance of stock, stock options or other equity securities.
Akouos, Inc. RESTRICTED STOCK AGREEMENTRestricted Stock Agreement • June 5th, 2020 • Akouos, Inc. • Pharmaceutical preparations • Delaware
This restricted stock award satisfies in full all commitments that the Company has to the Participant with respect to the issuance of stock, stock options or other equity securities.
Certain identified information has been marked in the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks denote omissions. LICENSE AGREEMENT between...License Agreement • June 5th, 2020 • Akouos, Inc. • Pharmaceutical preparations • New York
This License Agreement (“Agreement”), effective as of October 27, 2017 (“Effective Date”), is made between Massachusetts Eye and Ear Infirmary, a Massachusetts corporation having offices located at 243 Charles Street, Boston MA 02114 and The Schepens Eye Research Institute, Inc., a Massachusetts non-profit corporation having offices located at 20 Staniford Street, Boston, MA 021214 (collectively, “MEE”) and Akouos, Inc., a Delaware corporation having offices at [**], United States (“Akouos”). Akouos and MEE shall hereinafter collectively be referred to as the “Parties” and each, individually, as a “Party”.
LEASE BETWEEN BOSTON HARBOR INDUSTRIAL DEVELOPMENT LLC AND AKOUOS, INC.Lease Agreement • June 5th, 2020 • Akouos, Inc. • Pharmaceutical preparations • Massachusetts
Certain identified information has been marked in the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks denote omissions. SUBLICENSE AGREEMENT between LONZA...Sublicense Agreement • June 5th, 2020 • Akouos, Inc. • Pharmaceutical preparations • New York
This Sublicense Agreement (“Agreement”), effective as of October 27, 2017 (“Effective Date”), is made between Lonza Houston, Inc., a Delaware corporation having a principal place of business at 8066 El Rio Street, Houston, Texas 77054, United States, (“Lonza”) and Akouos, Inc., a Delaware corporation having a principal place of business at [**], United States (“Akouos”). Akouos and Lonza shall hereinafter collectively be referred to as the “Parties” and each, individually, as a “Party”.
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • June 5th, 2020 • Akouos, Inc. • Pharmaceutical preparations • Delaware
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 27th day of February, 2020, by and among Akouos, Inc., a Delaware corporation (the “Company”) and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”, along with any additional investors that become a party to this Agreement in accordance with Subection 6.9 hereof.
